TAT-10: Directing Alpha-emitting Conjugates to Cancer Chromatin via PARP-1

Kanazawa, Japan (UroToday.com) Poly (ADP-ribose) Polymerase (PARP-1) is a very abundant nuclear protein. High risk neuroblastoma over-expresses PARP-1 and we plan to use this feature to selectively target the neuroblastoma in treating the cancer chromatin. At211-MM4 was evaluated in vitro for the pharmacology and cytotoxicity in a panel of neuroblastoma cell lines.

IMR-05, SK-N-SH and NLF were the most sensitive cell line whereas Be-2-c was the most resistant. At211-MM4 therapy showed significant DNA damage as measured by gH2AX.  Interestingly therapy caused the most resistant cell line Be-2-c to increase PARP-1 expression. As expected, IMR-05 results in vitro translated into the highest therapeutic efficacy in in vivo models.

Presented By: Mehran Makvandi from University of Pennsylvania Perelman School of Medicine, Department of Radiology and Division of Nuclear Medicine

Written By: William Carithers, Lawrence Berkeley National Laboratory

at the 10th International Symposium on Targeted Alpha Therapy (TAT-10)  May 31 - June 1, 2017 - Kanazawa, Japan.

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.